The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma
Open accessAbstract
BACKGROUND: Mutations in hedgehog pathway genes, primarily genes encoding patched homologue 1 (PTCH1) and smoothened homologue (SMO), occur in basal-cell carcinoma. In a phase 1 clinical trial, we assessed the safety and pharmacokinetics of GDC-0449, a small-molecule inhibitor of SMO, and responses of metastatic or locally advanced basal-cell carcinoma to the drug. METHODS: We selected 33 patients with metastatic or locally advanced basal-cell carcinoma to receive oral GDC-0449 at one of three doses; 17 patients received 150 mg per day, 15 patients received 270 mg per day, and 1 patient received 540 mg per day. We assessed tumor responses with the use of Response Evaluation Criteria in Solid Tumors (RECIST), physical examination, or both. Molecular aspects of the tumors were examined. RESULTS: The median duration of the study treatment was 9.8 months. Of the 33 patients, 18 had an objective response to GDC-0449, according to assessment on imaging (7 patients), physical examination (10 patients), or both (1 patient). Of the patients who had a response, 2 had a complete response and 16 had a partial response. The other 15 patients had either stable disease (11 patients) or progressive disease (4 patients). Eight grade 3 adverse events that were deemed to be possibly related to the study drug were reported in six patients, including four with fatigue, two with hyponatremia, one with muscle spasm, and one with atrial fibrillation. One grade 4 event, asymptomatic hyponatremia, was judged to be unrelated to GDC-0449. One patient withdrew from the study because of adverse events. We found evidence of hedgehog signaling in tumors that responded to the treatment. CONCLUSIONS: GDC-0449, an orally active small molecule that targets the hedgehog pathway, appears to have antitumor activity in locally advanced or metastatic basal-cell carcinoma. (ClinicalTrials.gov number, NCT00607724.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
(1968) · American Association of Industrial Nurses Journal · doi:10.1177/216507996801601208 · Cited by 8,798
Hedgehog signaling in animal development: paradigms and principles
Ingham, P. W., & McMahon, A. P. (2001) · Genes & Development · doi:10.1101/gad.938601 · Cited by 2,985
Mutations of the Human Homolog of Drosophila patched in the Nevoid Basal Cell Carcinoma Syndrome
Hahn, H., Wicking, C., Zaphiropoulos, P. G., Gailani, M. R., Shanley, S., Chidambaram, A., Vorechovsky, I., Holmberg, E., Unden, A. B., Gillies, S., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81268-4 · Cited by 2,022
Human Homolog of patched , a Candidate Gene for the Basal Cell Nevus Syndrome
Johnson, R. L., Rothman, A. L., Xie, J., Goodrich, L. V., Bare, J. W., Bonifas, J. M., Quinn, A. G., Myers, R. M., Cox, D. R., Epstein, E. H., et al. (1996) · Science · doi:10.1126/science.272.5268.1668 · Cited by 1,857
Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened
Chen, J. K., Taipale, J., Cooper, M. K., & Beachy, P. A. (2002) · Genes & Development · doi:10.1101/gad.1025302 · Cited by 1,465
Activating Smoothened mutations in sporadic basal-cell carcinoma
Xie, J., Murone, M., Luoh, S.-M., Ryan, A., Gu, Q., Zhang, C., Bonifas, J. M., Lam, C.-W., Hynes, M., Goddard, A., et al. (1998) · Nature · doi:10.1038/34201 · Cited by 1,334
Self-citationTreatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449
Rudin, C. M., Hann, C. L., Laterra, J., Yauch, R. L., Callahan, C. A., Fu, L., Holcomb, T., Stinson, J., Gould, S. E., Coleman, B., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902903 · Cited by 1,019
Self-citationA paracrine requirement for hedgehog signalling in cancer
Yauch, R. L., Gould, S. E., Scales, S. J., Tang, T., Tian, H., Ahn, C. P., Marshall, D., Fu, L., Januario, T., Kallop, D., et al. (2008) · Nature · doi:10.1038/nature07275 · Cited by 961
Self-citationTargeting the Hedgehog pathway in cancer
Rubin, L. L., & de Sauvage, F. J. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2086 · Cited by 949
Self-citation
Cited by
Hallmarks of Cancer: New Dimensions
Hanahan, D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1059 · Cited by 9,887
Vincent, A., Herman, J., Schulick, R., Hruban, R. H., & Goggins, M. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62307-0 · Cited by 2,586
Li, D., Xie, K., Wolff, R., & Abbruzzese, J. L. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15841-8 · Cited by 1,719
Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
Sekulic, A., Migden, M. R., Oro, A. E., Dirix, L., Lewis, K. D., Hainsworth, J. D., Solomon, J. A., Yoo, S., Arron, S. T., Friedlander, P. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113713 · Cited by 1,464
Self-citationTargeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update
Takebe, N., Miele, L., Harris, P. J., Jeong, W., Bando, H., Kahn, M., Yang, S. X., & Ivy, S. P. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.61 · Cited by 1,298
A position statement on NAFLD/NASH based on the EASL 2009 special conference
Ratziu, V., Bellentani, S., Cortez-Pinto, H., Day, C., & Marchesini, G. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.04.008 · Cited by 1,058
Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449
Rudin, C. M., Hann, C. L., Laterra, J., Yauch, R. L., Callahan, C. A., Fu, L., Holcomb, T., Stinson, J., Gould, S. E., Coleman, B., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902903 · Cited by 1,019
Self-citationTargeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways
Takebe, N., Harris, P. J., Warren, R. Q., & Ivy, S. P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.196 · Cited by 992
Breast cancer: Biology, biomarkers, and treatments
Barzaman, K., Karami, J., Zarei, Z., Hosseinzadeh, A., Kazemi, M. H., Moradi-Kalbolandi, S., Safari, E., & Farahmand, L. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106535 · Cited by 973
Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma
Yauch, R. L., Dijkgraaf, G. J. P., Alicke, B., Januario, T., Ahn, C. P., Holcomb, T., Pujara, K., Stinson, J., Callahan, C. A., Tang, T., et al. (2009) · Science · doi:10.1126/science.1179386 · Cited by 839
Self-citationGenomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations
Brastianos, P. K., Horowitz, P. M., Santagata, S., Jones, R. T., McKenna, A., Getz, G., Ligon, K. L., Palescandolo, E., Van Hummelen, P., Ducar, M. D., et al. (2013) · Nature Genetics · doi:10.1038/ng.2526 · Cited by 651
Von Hoff, D. D., Stephenson, J. J., Rosen, P., Loesch, D. M., Borad, M. J., Anthony, S., Jameson, G., Brown, S., Cantafio, N., Richards, D. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5983 · Cited by 647
Self-citationCatenacci, D. V. T., Junttila, M. R., Karrison, T., Bahary, N., Horiba, M. N., Nattam, S. R., Marsh, R., Wallace, J., Kozloff, M., Rajdev, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.8719 · Cited by 561
Pancreatic cancer: from state-of-the-art treatments to promising novel therapies
Garrido-Laguna, I., & Hidalgo, M. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.53 · Cited by 565
Inhibiting the Hedgehog Pathway in Patients with the Basal-Cell Nevus Syndrome
Tang, J. Y., Mackay-Wiggan, J. M., Aszterbaum, M., Yauch, R. L., Lindgren, J., Chang, K., Coppola, C., Chanana, A. M., Marji, J., Bickers, D. R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113538 · Cited by 547
Self-citationLoRusso, P. M., Rudin, C. M., Reddy, J. C., Tibes, R., Weiss, G. J., Borad, M. J., Hann, C. L., Brahmer, J. R., Chang, I., Darbonne, W. C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2745 · Cited by 544
Self-citationItraconazole, a Commonly Used Antifungal that Inhibits Hedgehog Pathway Activity and Cancer Growth
Kim, J., Tang, J. Y., Gong, R., Kim, J., Lee, J. J., Clemons, K. V., Chong, C. R., Chang, K. S., Fereshteh, M., Gardner, D., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.02.027 · Cited by 527
Cameron, M. C., Lee, E., Hibler, B. P., Barker, C. A., Mori, S., Cordova, M., Nehal, K. S., & Rossi, A. M. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.03.060 · Cited by 525
Targeting Hedgehog — a Cancer Stem Cell Pathway
Merchant, A. A., & Matsui, W. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2846 · Cited by 500
Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma
Bonilla, X., Parmentier, L., King, B., Bezrukov, F., Kaya, G., Zoete, V., Seplyarskiy, V. B., Sharpe, H. J., McKee, T., Letourneau, A., et al. (2016) · Nature Genetics · doi:10.1038/ng.3525 · Cited by 490
Self-citationA highlight on Sonic hedgehog pathway
Carballo, G. B., Honorato, J. R., de Lopes, G. P. F., & Spohr, T. C. L. D. S. E. (2018) · Cell Communication and Signaling · doi:10.1186/s12964-018-0220-7 · Cited by 460
Ellis, L. M., Bernstein, D. S., Voest, E. E., Berlin, J. D., Sargent, D., Cortazar, P., Garrett-Mayer, E., Herbst, R. S., Lilenbaum, R. C., Sima, C., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.8009 · Cited by 442
Hedgehog beyond medulloblastoma and basal cell carcinoma
Teglund, S., & Toftgård, R. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.01.003 · Cited by 426
Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation
Zheng, D., Giljohann, D. A., Chen, D. L., Massich, M. D., Wang, X.-Q., Iordanov, H., Mirkin, C. A., & Paller, A. S. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118425109 · Cited by 409
Nault, J.-C., Couchy, G., Balabaud, C., Morcrette, G., Caruso, S., Blanc, J.-F., Bacq, Y., Calderaro, J., Paradis, V., Ramos, J., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.11.042 · Cited by 401
The Hedgehog's tale: developing strategies for targeting cancer
Ng, J. M. Y., & Curran, T. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3079 · Cited by 398
Dijkgraaf, G. J. P., Alicke, B., Weinmann, L., Januario, T., West, K., Modrusan, Z., Burdick, D., Goldsmith, R., Robarge, K., Sutherlin, D., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2876 · Cited by 363
Self-citationTargeting Breast Cancer Stem Cells
Liu, S., & Wicha, M. S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.5388 · Cited by 356
Beauchamp, E. M., Ringer, L., Bulut, G., Sajwan, K. P., Hall, M. D., Lee, Y.-C., Peaceman, D., Özdemirli, M., Rodriguez, O., Macdonald, T. J., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42874 · Cited by 351
Translating cancer research into targeted therapeutics
de Bono, J. S., & Ashworth, A. (2010) · Nature · doi:10.1038/nature09339 · Cited by 335
Activation of the hedgehog-signaling pathway in human cancer and the clinical implications
Yang, L., Xie, G., Fan, Q., & Xie, J. (2010) · Oncogene · doi:10.1038/onc.2009.392 · Cited by 331
Discovery of NVP-LDE225, a Potent and Selective Smoothened Antagonist
Pan, S., Wu, X., Jiang, J., Gao, W., Wan, Y., Cheng, D., Han, D., Liu, J., Englund, N. P., Wang, Y., et al. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml1000307 · Cited by 325
Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition
Tang, Y., Gholamin, S., Schubert, S., Willardson, M. I., Lee, A., Bandopadhayay, P., Bergthold, G., Masoud, S., Nguyen, B., Vue, N., et al. (2014) · Nature Medicine · doi:10.1038/nm.3613 · Cited by 314
Pollack, I. F., Agnihotri, S., & Broniscer, A. (2019) · Journal of Neurosurgery: Pediatrics · doi:10.3171/2018.10.peds18377 · Cited by 314
Cancer stem cells: problems for therapy?
Alison, M. R., Lim, S. M., & Nicholson, L. J. (2011) · The Journal of Pathology · doi:10.1002/path.2793 · Cited by 312
Kim, J., Lee, J. J., Kim, J., Gardner, D., & Beachy, P. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006822107 · Cited by 304
Hedgehog Signaling: From Basic Biology to Cancer Therapy
Wu, F., Zhang, Y., Sun, B., McMahon, A. P., & Wang, Y. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.02.010 · Cited by 302
Activating FGFR2–RAS–BRAF Mutations in Ameloblastoma
Brown, N. A., Rolland, D., McHugh, J. B., Weigelin, H. C., Zhao, L., Lim, M. S., Elenitoba-Johnson, K. S. J., & Betz, B. L. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1069 · Cited by 298
Kim, D. J., Kim, J., Spaunhurst, K., Montoya, J., Khodosh, R., Chandra, K., Fu, T., Gilliam, A., Molgo, M., Beachy, P. A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.9525 · Cited by 289
Hedgehog Partial Agonism Drives Warburg-like Metabolism in Muscle and Brown Fat
Teperino, R., Amann, S., Bayer, M., McGee, S. L., Loipetzberger, A., Connor, T., Jaeger, C., Kammerer, B., Winter, L., Wiche, G., et al. (2012) · Cell · doi:10.1016/j.cell.2012.09.021 · Cited by 283
Cartilage tumours and bone development: molecular pathology and possible therapeutic targets
Bovée, J. V. M. G., Hogendoorn, P. C. W., Wunder, J. S., & Alman, B. A. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2869 · Cited by 283
Hehlmann, R. (2012) · Blood · doi:10.1182/blood-2012-03-380147 · Cited by 273
Review: Targeting the Hedgehog pathway in cancer
Gupta, S., Takebe, N., & LoRusso, P. (2010) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834010366430 · Cited by 259
Self-citationCancer Stem Cell-Specific Scavenger Receptor CD36 Drives Glioblastoma Progression
Hale, J. S., Otvos, B., Sinyuk, M., Alvarado, A. G., Hitomi, M., Stoltz, K., Wu, Q., Flavahan, W., Levison, B., Johansen, M. L., et al. (2014) · Stem Cells · doi:10.1002/stem.1716 · Cited by 258
Structural basis for Smoothened receptor modulation and chemoresistance to anticancer drugs
Wang, C., Wu, H., Evron, T., Vardy, E., Han, G. W., Huang, X.-P., Hufeisen, S. J., Mangano, T. J., Urban, D. J., Katritch, V., et al. (2014) · Nature Communications · doi:10.1038/ncomms5355 · Cited by 253
Hypoxia triggers hedgehog-mediated tumor-stromal interactions in pancreatic cancer
Spivak-Kroizman, T. R., Hostetter, G., Posner, R., Aziz, M., Hu, C., Demeure, M. J., Von Hoff, D., Hingorani, S. R., Palculict, T. B., Izzo, J., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-11-1433 · Cited by 202
A cell identity switch allows residual BCC to survive Hedgehog pathway inhibition
Biehs, B., Dijkgraaf, G. J. P., Piskol, R., Alicke, B., Boumahdi, S., Peale, F., Gould, S. E., & de Sauvage, F. J. (2018) · Nature · doi:10.1038/s41586-018-0596-y · Cited by 137
Wong, H., Choo, E. F., Alicke, B., Ding, X., La, H., McNamara, E., Theil, F.-P., Tibbitts, J., Friedman, L. S., Hop, C. E. C. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0738 · Cited by 133
Hedgehog pathway inhibitors promote adaptive immune responses in basal cell carcinoma
Otsuka, A., Dreier, J., Cheng, P. F., Nägeli, M., Lehmann, H., Felderer, L., Frew, I. J., Matsushita, S., Levesque, M. P., & Dummer, R. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2110 · Cited by 106
Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma
D’Angelo, S. P., Richards, A. L., Conley, A. P., Woo, H. J., Dickson, M. A., Gounder, M., Kelly, C., Keohan, M. L., Movva, S., Thornton, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30874-8 · Cited by 60
The SHH/GLI signaling pathway: a therapeutic target for medulloblastoma
Lospinoso Severini, L., Ghirga, F., Bufalieri, F., Quaglio, D., Infante, P., & Di Marcotullio, L. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1823967 · Cited by 61
Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders
Schadt, E. E., Buchanan, S., Brennand, K. J., & Merchant, K. M. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00252 · Cited by 39
Yoon, J., Apicelli, A. J., & Pavlopoulos, T. V. (2018) · JAAD Case Reports · doi:10.1016/j.jdcr.2017.11.001 · Cited by 32
Subhadarshani, S., Athar, M., & Elmets, C. A. (2020) · Current Dermatology Reports · doi:10.1007/s13671-020-00307-0 · Cited by 21
Non-cell-autonomous signaling by Shh in tumors: challenges and opportunities for therapeutic targets
Bijlsma, M. F., & Roelink, H. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.497488 · Cited by 11
Metadata
- Authors
- Von Hoff, D. D., LoRusso, P. M., Rudin, C. M., Reddy, J. C., Yauch, R. L., Tibes, R., Weiss, G. J., Borad, M. J., Hann, C. L., Brahmer, J. R., Mackey, H. M., Lum, B. L., Darbonne, W. C., Marsters, J. C., de Sauvage, F. J., & Low, J. A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-09-17
- Volume
- 361
- Issue
- 12
- Pages
- 1164-1172
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1965431780
- Cited by
- 1,109
- References
- 15
- FWCI
- 51.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.